SOMAVAC® Medical Solutions Revenue
Biotechnology Research • 
Bartlett, Tennessee, United States • 11-20 Employees
SOMAVAC® Medical Solutions revenue & valuation
| Annual revenue | $941,105 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,100,000 |
| Total funding | $10,885,000 |
Key Contact at SOMAVAC® Medical Solutions
Frankie Mead
Vice President of Sales
Company overview
| Headquarters | 3144 Stage Post Dr, Suite 101, Memphis, Tennessee 38133, US |
| Phone number | +18337662822 |
| Website | |
| NAICS | 541714 |
| SIC | 384 |
| Keywords | Medical Device, Healthcare, Startup, General Surgery, Medtech, Plastic Surgery, Abdominoplasty, Reconstructive Surgery, Breast Surgery, Plastic Surgeon, Womenshealth, Hernia, Breastcancer, Breast Surgeons, Womenshealthtech, General Surgeons |
| Founded | 2016 |
| Employees | 11-20 |
| Socials |
SOMAVAC® Medical Solutions Email Formats
SOMAVAC® Medical Solutions uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@somavac.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@somavac.com | 50% |
{first name}.{last name} | john.doe@somavac.com | 33.3% |
{first initial} | j@somavac.com | 16.7% |
About SOMAVAC® Medical Solutions
SOMAVAC® Medical Solutions, Inc. is a MedTech company developing negative pressure therapy solutions for breast cancer recovery. Our platforms are led by our patented SOMAVAC® Deep Tissue Negative Pressure Therapy which is the first powered negative pressure therapy device cleared for seroma prophylaxis. For patients undergoing breast reconstruction and/or mastectomies, negative pressure delivered by SOMAVAC® removes fluid as it is produced, obliterates dead space, and holds tissues together which have been shown to prevent seromas. Seromas can lead to surgical complications like surgical site infections, wound dehiscence, etc. SOMAVAC® is FDA cleared for seroma prophylaxis. For more complex procedures, our recent patent combines SOMAVAC®'s Deep Tissue Negative Pressure Therapy (dtNPT) with the added benefit of closed-incision negative pressure wound therapy (ciNPWT). This patent is for the only comprehensive device that allows surgeons to optimize surgical outcomes with negative pressure therapy both inside the surgical site and outside the incision which creates a new medical device category and deepens the penetration of the $1.1B immediate US Market.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
SOMAVAC® Medical Solutions has 3 employees across 2 departments.
Departments
Number of employees
Funding Data
Explore SOMAVAC® Medical Solutions's funding history, including investment rounds, total capital raised, and key backers.
SOMAVAC® Medical Solutions Tech Stack
Discover the technologies and tools that power SOMAVAC® Medical Solutions's digital infrastructure, from frameworks to analytics platforms.
WordPress themes
Video players
Analytics
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Security
Programming languages
Blogs
JavaScript libraries
Finland
Spain
Israel
United Kingdom
Taiwan, Province of China
Poland
Frequently asked questions
4.8
40,000 users
